NCT00356590View on ClinicalTrials.gov

Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trial 016.0012

PHASE3CompletedINTERVENTIONAL

Enrollment

468

Participants

Timeline

Start Date

December 31, 1998

Primary Completion Date

December 31, 2008

Study Completion Date

April 30, 2009

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL

Etanercept

Etanercept (TNFR:Fc) will be administered 50 mg per week as two 25 mg subcutaneous injections at separate sites, given either on the same day or 3 or 4 days apart.